Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina

Executive Summary

• Hemostemix Inc. announced that Croom Lawrence will present clinical data on the treatment of Severe Angina Pectoris using VesCell™ (ACP-01) at a company webinar on September 18, 2025.
• The presentation highlights results from a clinical pilot study published in Circulation, demonstrating significant improvements in exercise tolerance, capacity, and symptom relief for patients with chronic stable angina who had exhausted maximal drug therapy.
• CEO Thomas Smeenk stated that the therapy is safe, clinically relevant, and statistically significant, serving as a foundation for future double-blind randomized clinical trials to seek global approval.

Key Details

• Presentation Details:
  • Presenter: Croom Lawrence
  • Title: "Treatment of Patients with Severe Angina Pectoris Using Intracoronarily Injected Autologous Blood-Borne Angiogenic Cell Precursors"
  • Date: Thursday, September 18, 2025
  • Context: Compares current standard of care to published results from a clinical pilot study of VesCell™ (ACP-01).
• Clinical Study Highlights (VesCell™ ACP-01 for Chronic Stable Angina):
  • Improved Exercise Tolerance: Six-minute walk distance increased from 333.65±26.56 meters (baseline) to 414.95±28.54 meters at 3 months (P<0.001) and 413.25±33.17 meters at 6 months (P<0.001).
  • Enhanced Exercise Capacity: Metabolic Equivalents (METs) rose from 5.62±0.52 (baseline) to 6.73±0.64 at 3 months (P<0.004) and 7.09±0.79 at 6 months (P<0.04).
  • Reduction in Ischemia: SPECT-MIBI perfusion defects decreased from 38.46±6.19% (baseline) to 23.89±5.79% at 3 months (P<0.004) and 21.05±5.16% at 6 months (P<0.005).
  • Symptom Relief: Canadian Cardiovascular Society (CCS) angina score improved from 2.1±0.19 (baseline) to 1.05±0.05 at 3 months and 1.18±0.13 at 6 months (P<0.001).
• Strategic Outlook:
  • Revenue from compassionate treatments under Florida SB 1768 and data from real-world patient experiences will fund a double-blind randomized clinical trial for global approval.
  • The company has completed seven clinical studies involving 318 subjects, with results published in 11 peer-reviewed publications.
  • A recent article in Cells (June 29, 2025) suggests ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation and fostering angiogenesis.

Notable Quotes

• "The painful, severe angina we are treating is caused by ischemia, a condition where blood flow is restricted to the heart muscle... The results of our study are a significant step forward because our ACP-01 therapy uses a unique approach: we harvest angiogenic stem cells from the patient's own blood. These patented cells are then able to seek out the ischemic injury, improve blood circulation, and reduce the disease's impact." — Thomas Smeenk, CEO
• "The therapy is demonstrated safe, clinically relevant, and statistically significant—including a better quality of life and less chest pain. Thus, ACP-01 offers renewed hope for patients who have exhausted traditional medical options." — Thomas Smeenk, CEO